SI-BONE, Inc. (NASDAQ:SIBN) SVP Michael A. Pisetsky sold 354 shares of the stock in a transaction on Friday, July 16th. The shares were sold at an average price of $29.10, for a total transaction of $10,301.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Shares of SI-BONE stock opened at $30.71 on Thursday. The company has a current ratio of 15.18, a quick ratio of 14.64 and a debt-to-equity ratio of 0.24. SI-BONE, Inc. has a 1 year low of $16.25 and a 1 year high of $37.21. The business’s 50-day simple moving average is $30.90. The company has a market cap of $1.01 billion, a PE ratio of -21.63 and a beta of 1.44.
SI-BONE (NASDAQ:SIBN) last issued its earnings results on Sunday, May 2nd. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.03. SI-BONE had a negative net margin of 56.06% and a negative return on equity of 31.92%. The company had revenue of $20.44 million for the quarter, compared to analysts’ expectations of $19.08 million. Research analysts predict that SI-BONE, Inc. will post -1.58 earnings per share for the current year.
Several brokerages have recently weighed in on SIBN. Truist increased their target price on shares of SI-BONE from $35.00 to $43.00 in a research note on Tuesday, May 4th. Truist Securities increased their target price on shares of SI-BONE from $35.00 to $43.00 in a research note on Tuesday, May 4th. Citigroup assumed coverage on shares of SI-BONE in a report on Tuesday, June 8th. They issued a “buy” rating on the stock. Needham & Company LLC upped their price target on shares of SI-BONE from $34.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, May 4th. Finally, assumed coverage on shares of SI-BONE in a report on Tuesday, June 8th. They issued a “buy” rating and a $40.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. SI-BONE presently has an average rating of “Buy” and a consensus price target of $38.50.
SI-BONE, Inc, a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain.
Featured Story: Analyst Ratings
Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.